Biased agonism and allosteric modulation of metabotropic glutamate receptor 5

Research output: Contribution to journalReview ArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Metabotropic glutamate receptors belong to class C G-protein-coupled receptors and consist of eight subtypes that are ubiquitously expressed throughout the central nervous system. In recent years, the metabotropic glutamate receptor subtype 5 (mGlu5) has emerged as a promising target for a broad range of psychiatric and neurological disorders. Drug discovery programs targetting mGlu5 are primarily focused on development of allosteric modulators that interact with sites distinct from the endogenous agonist glutamate. Significant efforts have seen mGlu5 allosteric modulators progress into clinical trials; however, recent failures due to lack of efficacy or adverse effects indicate a need for a better understanding of the functional consequences of mGlu5 allosteric modulation. Biased agonism is an interrelated phenomenon to allosterism, describing how different ligands acting through the same receptor can differentially influence signaling to distinct transducers and pathways. Emerging evidence demonstrates that allosteric modulators can induce biased pharmacology at the level of intrinsic agonism as well as through differential modulation of orthosteric agonist-signaling pathways. Here, we present key considerations in the discovery and development of mGlu5 allosteric modulators and the opportunities and pitfalls offered by biased agonism and modulation.

Original languageEnglish
Pages (from-to)2323-2338
Number of pages16
JournalClinical science (London, England : 1979)
Volume132
Issue number21
DOIs
Publication statusPublished - 15 Nov 2018

Keywords

  • allosteric
  • biased agonism
  • drug discovery
  • metabotropic glutamate receptor

Cite this

@article{5d61822a2a4a4c3ea1863b7cc80a3c8a,
title = "Biased agonism and allosteric modulation of metabotropic glutamate receptor 5",
abstract = "Metabotropic glutamate receptors belong to class C G-protein-coupled receptors and consist of eight subtypes that are ubiquitously expressed throughout the central nervous system. In recent years, the metabotropic glutamate receptor subtype 5 (mGlu5) has emerged as a promising target for a broad range of psychiatric and neurological disorders. Drug discovery programs targetting mGlu5 are primarily focused on development of allosteric modulators that interact with sites distinct from the endogenous agonist glutamate. Significant efforts have seen mGlu5 allosteric modulators progress into clinical trials; however, recent failures due to lack of efficacy or adverse effects indicate a need for a better understanding of the functional consequences of mGlu5 allosteric modulation. Biased agonism is an interrelated phenomenon to allosterism, describing how different ligands acting through the same receptor can differentially influence signaling to distinct transducers and pathways. Emerging evidence demonstrates that allosteric modulators can induce biased pharmacology at the level of intrinsic agonism as well as through differential modulation of orthosteric agonist-signaling pathways. Here, we present key considerations in the discovery and development of mGlu5 allosteric modulators and the opportunities and pitfalls offered by biased agonism and modulation.",
keywords = "allosteric, biased agonism, drug discovery, metabotropic glutamate receptor",
author = "Trinh, {Phuc N.H.} and May, {Lauren T.} and Katie Leach and Gregory, {Karen J.}",
year = "2018",
month = "11",
day = "15",
doi = "10.1042/CS20180374",
language = "English",
volume = "132",
pages = "2323--2338",
journal = "Clinical Science and Molecular Medicine",
issn = "0009-9287",
publisher = "Portland Press",
number = "21",

}

Biased agonism and allosteric modulation of metabotropic glutamate receptor 5. / Trinh, Phuc N.H.; May, Lauren T.; Leach, Katie; Gregory, Karen J.

In: Clinical science (London, England : 1979), Vol. 132, No. 21, 15.11.2018, p. 2323-2338.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Biased agonism and allosteric modulation of metabotropic glutamate receptor 5

AU - Trinh, Phuc N.H.

AU - May, Lauren T.

AU - Leach, Katie

AU - Gregory, Karen J.

PY - 2018/11/15

Y1 - 2018/11/15

N2 - Metabotropic glutamate receptors belong to class C G-protein-coupled receptors and consist of eight subtypes that are ubiquitously expressed throughout the central nervous system. In recent years, the metabotropic glutamate receptor subtype 5 (mGlu5) has emerged as a promising target for a broad range of psychiatric and neurological disorders. Drug discovery programs targetting mGlu5 are primarily focused on development of allosteric modulators that interact with sites distinct from the endogenous agonist glutamate. Significant efforts have seen mGlu5 allosteric modulators progress into clinical trials; however, recent failures due to lack of efficacy or adverse effects indicate a need for a better understanding of the functional consequences of mGlu5 allosteric modulation. Biased agonism is an interrelated phenomenon to allosterism, describing how different ligands acting through the same receptor can differentially influence signaling to distinct transducers and pathways. Emerging evidence demonstrates that allosteric modulators can induce biased pharmacology at the level of intrinsic agonism as well as through differential modulation of orthosteric agonist-signaling pathways. Here, we present key considerations in the discovery and development of mGlu5 allosteric modulators and the opportunities and pitfalls offered by biased agonism and modulation.

AB - Metabotropic glutamate receptors belong to class C G-protein-coupled receptors and consist of eight subtypes that are ubiquitously expressed throughout the central nervous system. In recent years, the metabotropic glutamate receptor subtype 5 (mGlu5) has emerged as a promising target for a broad range of psychiatric and neurological disorders. Drug discovery programs targetting mGlu5 are primarily focused on development of allosteric modulators that interact with sites distinct from the endogenous agonist glutamate. Significant efforts have seen mGlu5 allosteric modulators progress into clinical trials; however, recent failures due to lack of efficacy or adverse effects indicate a need for a better understanding of the functional consequences of mGlu5 allosteric modulation. Biased agonism is an interrelated phenomenon to allosterism, describing how different ligands acting through the same receptor can differentially influence signaling to distinct transducers and pathways. Emerging evidence demonstrates that allosteric modulators can induce biased pharmacology at the level of intrinsic agonism as well as through differential modulation of orthosteric agonist-signaling pathways. Here, we present key considerations in the discovery and development of mGlu5 allosteric modulators and the opportunities and pitfalls offered by biased agonism and modulation.

KW - allosteric

KW - biased agonism

KW - drug discovery

KW - metabotropic glutamate receptor

UR - http://www.scopus.com/inward/record.url?scp=85056054362&partnerID=8YFLogxK

U2 - 10.1042/CS20180374

DO - 10.1042/CS20180374

M3 - Review Article

VL - 132

SP - 2323

EP - 2338

JO - Clinical Science and Molecular Medicine

JF - Clinical Science and Molecular Medicine

SN - 0009-9287

IS - 21

ER -